Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 42,300 shares, a decrease of 19.3% from the September 15th total of 52,400 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily volume of 66,600 shares, the days-to-cover ratio is currently 0.6 days.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Turtle Creek Wealth Advisors LLC acquired a new position in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 71,500 shares of the company’s stock, valued at approximately $64,000. Turtle Creek Wealth Advisors LLC owned 0.42% of Talphera at the end of the most recent quarter. 37.67% of the stock is currently owned by institutional investors and hedge funds.

Talphera Price Performance

Shares of Talphera stock traded up $0.02 on Tuesday, hitting $0.80. 12,211 shares of the company’s stock traded hands, compared to its average volume of 85,685. The company has a fifty day moving average of $0.90 and a two-hundred day moving average of $0.96. Talphera has a one year low of $0.43 and a one year high of $1.61. The company has a market capitalization of $13.60 million, a price-to-earnings ratio of -0.87 and a beta of 0.32.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. Equities research analysts anticipate that Talphera will post -0.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Talphera in a research note on Friday, August 16th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.